DXCM logo

DEXCOM, INC. (DXCM)$72.10

Market Cap: 31.47 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for DEXCOM, INC. (DXCM).

HEALTHCARE
MEDICAL DEVICES
DCF ready

Valuation

28.4x

EV/FCF, 3.5% FCF yield

Quality

30.5%

ROIC, 23.1% FCF margin

Growth

19.3%

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 1.9x current ratio

Superinvestors

1

Top: First Eagle Investment Management (0.0%)

Strengths to research

  • Revenue compounded at 19.3% over five years.
  • Free cash flow compounded at 31.2% over five years.
  • Return on equity is strong at 30.5%.
  • Free cash flow margin is healthy at 23.1%.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for DXCM.

Grade B
83
/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best
DXCM
Target
DEXCOM, INC.$31.5B34.5x28.4x30.5%19.3%23.1%60.1%-0.8xN/A
EWEdwards Lifesciences Corp.$44.0B46.9x30.8x10.4%6.7%22.0%78.0%-2.1xN/A
STESTERIS plc$22.0B34.9x30.6x7.2%12.5%14.3%44.0%1.3xN/A
MDTMedtronic plc$107.0B21.8x20.2x9.7%3.0%15.5%N/A-0.3xN/A
SYKStryker Corp.$145.6B37.7x33.0x14.5%11.8%17.1%64.0%-0.6xN/A
BIOBio-Rad Laboratories Inc.$6.5B10.3x19.2x8.8%0.3%14.5%51.9%3.2xN/A
BSXBoston Scientific$154.2B29.8x41.6x11.9%15.2%18.2%69.0%-0.4xN/A
BRKRBruker Corp.$6.2B-304.6x178.8x-0.2%11.6%1.3%45.9%5.4xN/A
ABTAbbott Labs$230.7B23.5x31.8x10.0%5.1%16.7%N/A0.5xN/A

Financial Charts

No financial data available for DXCM (annual).

1 superinvestors own DXCM

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
First Eagle Investment Management

First Eagle Investment Management

58$4,0000.00%0.0%